PerkinElmer gets FDA approval for kit to automate TB test

By LabPulse.com staff writers

September 22, 2022 -- PerkinElmer’s Oxford Immunotec business on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved the use of T-Cell Select reagent kit for the automation of its T-Spot.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories.

The reagent kit allows for a more automated workflow and is designed to reduce hands-on time for lab personnel and lower overall costs, the firm said.

T-Cell Select is a peripheral blood mononuclear cell (PBMC) isolation reagent that uses positive selection of PBMCs with magnetic bead-based cell separation to automate and simplify the preparation of cells for the T-Spot.TB test, a globally regulated enzyme-linked immunosorbent spot (ELISPOT) interferon gamma release assay (IGRA) for detecting latent TB infection.

"Automation closes the gap between ELISPOT and ELISA [enzyme-linked immunoassay] laboratory workflows, enabling more laboratories to offer the ... T-Spot.TB test to more physicians," Phill Keefe, CEO of PerkinElmer's Oxford Immunotec division, said in a statement.

PerkinElmer added that the kits are available throughout Europe in countries that accept CE marking; South Korea, through its Ministry of Food and Drug Safety; and China, through its National Medical Products Administration (NMPA).

Video from AACC: PerkinElmer on diagnostics, acquisitions
Greg Stock, general manager of PerkinElmer’s Euroimmun business, discussed products and technologies on display at AACC 2022, as well as the integration...
PerkinElmer Q2 revenues flat year over year
PerkinElmer on Monday reported second quarter revenues of $1.23 billion, flat year-over-year but surpassing Wall Street analysts’ average estimate of...
PerkinElmer inks deal to divest businesses
Moving closer to its goal of becoming solely a life sciences and diagnostics company, PerkinElmer said Monday that it has signed an agreement to divest...
Qiagen marks milestone for TB blood test
Qiagen's QuantiFeron blood test has been used to screen patients for tuberculosis (TB) infection more than 100 million times since its launch, the company...
PerkinElmer to buy Oxford Immunotec Global
PerkinElmer plans to acquire Oxford Immunotec Global and that company's infectious disease testing technology in a deal worth $591 million. The purchase...

Copyright © 2022 LabPulse.com

Last Updated mp 9/22/2022 11:40:00 AM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current